Strategic Intelligence as a Service

Unlike legacy providers that sell static database subscriptions and leave your team to decipher complex market signals, Augmentios provides a high-fidelity strategic deliverable. Simply identify your target asset or competitive landscape, and our platform hands back a forensic audit of reporting gaps, operational decay, and regulatory moats. We provide the "ground truth" so you can execute with absolute certainty.

Fiduciary Integrity and Strategic Oversight

Augmentios is explicitly designed to keep the Strategic Lead in full control. Our platform features an intelligent transparency interface that uses active, declarative logic to flag specific operational and valuation risks for immediate review. This "Glass Box" architecture ensures that every signal—from reporting blackouts to site-level decay—is sourced, timestamped, and defensible to your board.

Forensic Logic Over "Clinical Archaeology"

Traditional due diligence relies on "Real-World Data" (RWD) and historical claims that merely predict the past. Augmentios utilizes programmatic, forward-looking forensics to map the true trajectory of an asset. By identifying hidden operational friction and scientific signals exactly where the FDA demands them, we tell sponsors and investors not just what happened, but what will happen next.

Neutral Intelligence, Zero Conflict of Interest

Large CROs often prioritize their own site networks, masking operational failures with expensive change orders. Augmentios is completely network-agnostic and operates on a flat-fee forensic model. By identifying the statistically optimal path for asset rescue or indication expansion on Day 1, we ensure your capital is protected from the "treatment-only" consulting cycle that drains peak revenue.

Accelerated Liquidity and NPV Protection

The DAPORT platform dramatically accelerates the time-to-truth. By reducing over 40 hours of manual diligence to a 60-minute forensic scan, we identify "Strategic Leverage Windows" that competitors miss. By mathematically preventing Refusals to File or binary clinical holds, Augmentios protects the $1M per day in NPV that is lost to operational drift and regulatory friction.

Elite Clinical Leadership and the "Founder Moat"

Unlike generic tech startups or disconnected software developers, Augmentios is led by Natalie Yeadon, a successfully exited serial founder with over 30 years of operational clinical leadership. With a proven track record of building and scaling a global tech platform for Top-20 Pharma clients, and direct experience commercializing blockbuster therapeutics like Herceptin® and IRESSA®, the company is driven by deep domain expertise. This ensures the platform is architected with true clinical governance and commercial understanding, perfectly aligning with the high-stakes needs of Chief Medical Officers.